Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of HX009 in advanced solid tumors
CTR20211292Phase 2Completed
- Sponsor
- Hansi Bio
- Start
- May 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of HX009 in Nonhematologic neoplasms, sponsored by Hansi Bio. Started May 2021; status: completed.
02
Drugs
HX009
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20211292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211292.